Triple negative breast cancer (TNBC)

This phase 1 trial tests whether combining several investigational immunotherapy drugs, with or without chemotherapy, can safely shrink advanced solid tumors. The study enrolls adults with cancers like non-small-cell lung cancer or triple-negative breast cancer that have progress…

This early-phase trial is testing an experimental drug called AB598, alone or with other cancer drugs, in 40 people with advanced solid tumors like lung, bladder, or breast cancer. The main goal is to check safety and find the right dose. It is not yet known if the drug helps shr…

This trial is testing whether combining chemotherapy with two immunotherapy drugs, given before surgery, can completely eliminate triple-negative breast cancer in people with stage II-III disease. Participants will receive six cycles of the combination, and the main goal is to se…

This phase 3 trial is testing whether adding an experimental immunotherapy drug called PM8002 to standard chemotherapy (nab-paclitaxel) can help people with advanced triple-negative breast cancer live longer without their disease worsening. The study enrolls women aged 18 to 70 w…

This early-phase study tests a new drug called RNDO-564, alone or with pembrolizumab, in adults with advanced solid tumors (like bladder, lung, or breast cancer) that have stopped responding to standard treatments. The main goals are to check safety, find the best dose, and see i…

This study tests whether adding the experimental drug onvansertib to standard chemotherapy (paclitaxel) can safely shrink tumors in people with triple-negative breast cancer that has spread. About 50 adults with advanced or metastatic disease will receive the combination. The goa…

This Phase 2 trial is testing a combination of two chemotherapy drugs, liposomal doxorubicin and carboplatin, given after surgery to people with early-stage triple negative breast cancer. The goal is to see if this treatment can reduce the risk of the cancer coming back. The stud…

This study is a long-term follow-up for 400 people who previously received A2 Bio gene therapy for various solid tumors, including colorectal, lung, pancreatic, and ovarian cancers. No new treatment is given; instead, researchers will track participants over time to check for del…

This study looks at how well the body of women with early triple-negative breast cancer can switch between burning fat and sugar for energy—a trait called metabolic flexibility. Researchers will test if different types of exercise (moderate cardio, high-intensity cardio, or stren…